Climb Bio (CLYM) Enterprise Value (2020 - 2026)
Climb Bio's (CLYM) quarterly Enterprise Value came in at -$109.6 million in Q1 2026, down 11.73% YoY from -$124.1 million in Q1 2025, and down 8.39% on a QoQ basis from -$101.1 million in Q4 2025.
Climb Bio (CLYM) Enterprise Value (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Enterprise Value data on file, last reported at -$109.6 million in Q1 2026.
- Quarterly Enterprise Value fell 11.73% year-over-year to -$109.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$109.6 million (down 11.73% YoY) and the FY2025 annual result came in at -$101.1 million, up 33.02% from the prior year.
- Enterprise Value eased to -$109.6 million in Q1 2026, from -$101.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$84.7 million in Q2 2025 to a low of -$261.7 million in Q3 2024.
- A 5-year average of -$130.8 million and a median of -$109.6 million in 2026 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value slumped 143.6% — and 2025, when it jumped 66.79%.
- Tracing CLYM's Enterprise Value over 5 years: stood at -$123.6 million in 2022, then gained by 5.66% to -$116.6 million in 2023, then declined by 29.47% to -$150.9 million in 2024, then surged by 33.02% to -$101.1 million in 2025, then slipped by 8.39% to -$109.6 million in 2026.
- The last three Enterprise Value figures came in at -$109.6 million (Q1 2026), -$101.1 million (Q4 2025), and -$86.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | -183.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -183.12 Mn |
| Mar 31, 2026 | -109.56 Mn |
| Dec 31, 2025 | -101.08 Mn |
| Sep 30, 2025 | -86.90 Mn |
| Jun 30, 2025 | -84.70 Mn |
| Mar 31, 2025 | -98.06 Mn |
| Dec 31, 2024 | -150.92 Mn |
| Sep 30, 2024 | -261.70 Mn |
| Jun 30, 2024 | -218.12 Mn |
| Mar 31, 2024 | -103.24 Mn |
| Dec 31, 2023 | -116.57 Mn |
| Sep 30, 2023 | -107.43 Mn |
| Jun 30, 2023 | -102.63 Mn |
| Mar 31, 2023 | -109.37 Mn |
| Dec 31, 2022 | -123.57 Mn |
| Sep 30, 2022 | -203.06 Mn |
| Jun 30, 2022 | -122.95 Mn |
| Mar 31, 2022 | -123.94 Mn |
| Dec 31, 2021 | -136.48 Mn |
| Sep 30, 2021 | -228.43 Mn |